Wal­mart is next in line on na­tion­al opi­oid set­tle­ment, pay­ing $3B+ for its role in epi­dem­ic

3 years ago
Pharma
Law

Al­ler­gan and Merz set­tle more Alzheimer's drug pay-for-de­lay al­le­ga­tions for $54M

3 years ago
Pharma
Law

Will the doc­tor see you now? Phar­ma sales reps jug­gle dig­i­tal and in-per­son calls amid docs’ se­lec­tive­ness

3 years ago
Marketing

Pri­vate in­vest­ment firm snaps up Pfiz­er fa­cil­i­ty in West­ern Aus­tralia

3 years ago
Deals
Manufacturing

Q&A: No­vo Nordisk sus­tain­abil­i­ty leader de­tails US 'C­i­ties,' pro cy­cling and more to dri­ve di­a­betes aware­ness

3 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er ad­vances Cib­in­qo TV cam­paign; Jazz teams again with can­cer non prof­it

3 years ago
Pharma
Marketing

A rare biotech IPO lands on Nas­daq, boost­ed by RA Cap­i­tal and a for­mer Eli Lil­ly drug

3 years ago
Financing

Sev­er­al biotechs con­tin­ue trend of lay­offs, pipeline culls as third quar­ter re­ports roll in

3 years ago
People
R&D

Sur­rozen paus­es PhI clin­i­cal tri­al in ul­cer­a­tive col­i­tis due to ad­verse events in liv­er

3 years ago
R&D

FDA con­tin­ues to ques­tion Arde­lyx CKD drug's ef­fect on clin­i­cal out­comes ahead of ad­comm meet­ing

3 years ago
FDA+

Up­dat­ed: FDA push­es to make opi­oid over­dose re­ver­sal agents OTC prod­ucts as com­pa­nies balk

3 years ago
FDA+

Up­dat­ed: One down, one to go: Ar­cutis' re­pur­posed As­traZeneca drug clears first PhI­II eczema tri­al

3 years ago
R&D

El­e­vate­Bio and Affi­ni-T part­ner on KRAS ther­a­pies; Cas­ma rais­es $46M to drug the cell’s garbage dis­pos­al sys­tem

3 years ago
News Briefing

Can an on­colyt­ic virus ther­a­py chal­lenge the stan­dard of care in blad­der can­cer? CG On­col­o­gy has $120M to find out

3 years ago
Financing

The crew that sold its lead IL-2 pro­gram to Roche is back with $93M to work on more next-gen I/O drugs

3 years ago
Financing
Startups

FDA be­stows ac­cel­er­at­ed ap­proval on Im­muno­Gen's ovar­i­an can­cer drug, with con­fir­ma­to­ry an­swer com­ing soon

3 years ago
FDA+

Roche dou­bles down on Jnana's drug dis­cov­ery plat­form, kick­ing off sec­ond deal with $50M cash — while biotech bags ...

3 years ago
Financing
Deals

In­di­v­ior snaps up Nar­can own­er for $145M up­front, with an eye on next-gen nasal spray

3 years ago
Deals

Hori­zon dou­bles down on Krys­texxa mar­ket­ing to physi­cians with ‘green stuff’ im­agery

3 years ago
Pharma
Marketing

No­vo Nordisk, GSK pause some Twit­ter ad spend­ing af­ter Musk takeover

3 years ago
Pharma

BioN­Tech ac­quires a for­mer No­var­tis man­u­fac­tur­ing fa­cil­i­ty in Sin­ga­pore

3 years ago
Pharma
Manufacturing

Mod­er­na touts 'su­pe­ri­or' an­ti­body lev­els against Omi­cron for au­tho­rized Covid-19 bi­va­lent boost­er

3 years ago
R&D
Pharma

SEC snatch­es Vi­a­tris in­for­ma­tion chief in $8M in­sid­er trad­ing scheme via cash pay­ments in In­dia

3 years ago
People
Pharma

Sat­suma backs away from com­mer­cial ef­forts af­ter mi­graine can­di­date fails to hit pri­ma­ry end­point

3 years ago
R&D
First page Previous page 428429430431432433434 Next page Last page
A service from the Financial Times